Meditech begins second stage of Phase II
Monday, 06 December, 2004
Meditech Research (ASX:MTR) has commenced the second stage of its Phase II trial of HyCAMP, its proprietary formulation of chemotherapeutic drug irinotecan in combination with hyaluronic acid.
The trial will examine the safety and efficacy of HyCAMP and compare it to irinotecan alone in 86 patients previously treated with 5-fluorouracil. The trial is expected to be completed in mid-2006.
In an earlier uncontrolled study testing HyCAMP in twelve patients, the treatment showed similar efficacy with improved safety.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
